4.7 Article

Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test-Retest Variability in Lung Cancer

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 51, Issue 11, Pages 1684-1690

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.079137

Keywords

tumor perfusion; PET-CT; radioactive water; lung cancer; parametric perfusion images

Ask authors/readers for more resources

Quantification of tumor perfusion using radioactive water ((H2O)-O-15) and PET is a promising method for monitoring treatment with antiangiogenic agents. However, use of dynamic (H2O)-O-15 scans together with a fully 3-dimensional clinical PET/CT scanner needs to be validated. The purpose of the present study was to assess validity and reproducibility of dynamic (H2O)-O-15 PET/CT scans for measuring tumor perfusion and validate the quantitative accuracy of parametric perfusion images. Methods: Eleven patients with non-small cell lung cancer were included in this study. Patients underwent 2 dynamic (H2O)-O-15 (370 MBq) PET scans on the same day. During the first scan, arterial blood was withdrawn continuously. Input functions were derived from blood sampler data and the ascending aorta as seen in the images themselves (image-derived input function [IDIF]). Parametric perfusion images were computed using a basis function implementation of the standard single-tissue-compartment model. Volumes of interest (VOls) were delineated on low-dose CT (LD-CT) and parametric perfusion images. Results: VOls could be accurately delineated on both LD-CT and parametric perfusion images. These parametric perfusion images had excellent image quality and quantitative accuracy when compared with perfusion values determined by nonlinear regression. Good correlation between perfusion values derived from the blood sampler input function and IDIF was found (Pearson correlation coefficient, r = 0.964; P < 0.001). Test-retest variability of tumor perfusion was 16% and 20% when delineated on LD-CT and parametric perfusion images, respectively. Conclusion: The use of ascending aorta IDIFs is an accurate alternative to arterial blood sampling for quantification of tumor perfusion. Image quality obtained with a clinical PET/CT scanner enables generation of accurate parametric perfusion images. VOls delineated on LD-CT have the highest reproducibility, and changes of more than 16% in tumor perfusion are likely to represent treatment effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Comparison between cardiac magnetic resonance stress T1 mapping and [15O]H2O positron emission tomography in patients with suspected obstructive coronary artery disease

Henk Everaars, Pepijn A. van Diemen, P. Stefan Biesbroek, Luuk H. G. A. Hopman, Michiel J. Bom, Stefan P. Schumacher, Ruben W. de Winter, Peter M. van de Ven, Pieter G. Raijmakers, Adriaan A. Lammertsma, Mark B. M. Hofman, Robin Nijveldt, Marco J. Gotte, Albert C. van Rossum, Ibrahim Danad, Roel S. Driessen, Paul Knaapen

Summary: This study aimed to compare cardiac magnetic resonance (CMR) measurement of T1 reactivity (Delta T1) with [O-15]H2O positron emission tomography (PET) measurements of quantitative myocardial perfusion. The results showed poor agreement between CMR stress T1 mapping and PET measurements of absolute myocardial perfusion. CMR stress T1 and Delta T1 were lower in vascular territories with reduced stress MBF, but had limited accuracy in detecting impaired myocardial perfusion.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer

Anna-Larissa N. Niemeijer, Daniela E. Oprea-Lager, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Berlinda J. de Wit-van der Veen, Idris Bahce, Danielle J. Vugts, Guus A. M. S. van Dongen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen

Summary: This study investigated the response of NSCLC patients to pembrolizumab monotherapy and the uptake of Zr-89-pembrolizumab in tumors, finding that patients with higher uptake had better responses to treatment. Although no significant correlation was found with PD-L1 or PD-1 immunohistochemistry, the injection of Zr-89-pembrolizumab was deemed safe in the study.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Eric Guedj, Andrea Varrone, Ronald Boellaard, Nathalie L. Albert, Henryk Barthel, Bart van Berckel, Matthias Brendel, Diego Cecchin, Ozgul Ekmekcioglu, Valentina Garibotto, Adriaan A. Lammertsma, Ian Law, Ivan Penuelas, Franck Semah, Tatjana Traub-Weidinger, Elsmarieke van de Giessen, Donatienne Van Weehaeghe, Silvia Morbelli

Summary: The guidelines summarize the current views of the EANM Neuro-Imaging Committee on [F-18]FDG-PET imaging of the brain, aiming to improve diagnostic impact in neurological, neurosurgical, and psychiatric practice. Updates include advances in PET technology, the impact of hyperglycemia in patients undergoing brain [F-18]FDG-PET, and typical brain metabolic patterns for neurodegenerative diseases.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner

Adrienne H. Brouwers, Joyce van Sluis, Johannes H. van Snick, Carolina P. Schroder, Inge O. Baas, Ronald Boellaard, Andor W. J. M. Glaudemans, Ronald J. H. Borra, Adriaan A. Lammertsma, Rudi A. J. O. Dierckx, Charalampos Tsoumpas

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative assessment of myelin density using [11C]MeDAS PET in patients with multiple sclerosis: a first-in-human study

Chris W. J. van der Weijden, Jan F. Meilof, Anouk van der Hoorn, Junqing Zhu, Chunying Wu, Yanming Wang, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Erik F. J. de Vries

Summary: This study aimed to evaluate [C-11]MeDAS as a PET tracer for myelin imaging in humans. The 2T3k model was found to be the optimal compartment model, and MLAIR2 was the best simplified method for quantification. [C-11]MeDAS PET can be used for quantification of myelin density in MS patients and is able to distinguish differences in myelin density within MS lesions.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Review Cell Biology

Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer

Melek Huyuk, Marta Fiocco, Pieter E. Postmus, Danielle Cohen, Jan H. von der Thusen

Summary: This systematic review and meta-analysis investigated the association between lymph node micrometastases in stage I-IIIA NSCLC patients and overall survival (OS) and disease-free survival (DFS) after surgical resection. The study found that patients with lymph node micrometastases detected through ancillary techniques had significantly poorer OS and DFS compared to patients without micrometastases. The 5-year OS and DFS rates were lower in the micrometastasis group compared to the no micrometastasis group.

HISTOPATHOLOGY (2023)

Article Endocrinology & Metabolism

Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals

Fiona Heeman, Denise Visser, Maqsood Yaqub, Sander Verfaillie, Tessa Timmers, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, Bart N. M. van Berckel, Ronald Boellaard, Adriaan A. Lammertsma, Sandeep S. Golla

Summary: Alzheimer's disease is characterized by reduced cerebral blood flow. This study compared the precision of different methods for measuring cerebral blood flow and found that relative blood flow methods had better repeatability than absolute blood flow methods. The high precision of relative blood flow may be due to a compensatory effect of the extraction fraction.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification

Anne M. Smith, Nancy A. Obuchowski, Norman L. Foster, Gregory Klein, P. David Mozley, Adriaan A. Lammertsma, Richard L. Wahl, John J. Sunderland, Jean-Luc Vanderheyden, Tammie L. S. Benzinger, Paul E. Kinahan, Dean F. Wong, Eric S. Perlman, Satoshi Minoshima, Dawn Matthews

Summary: Standardized approach in acquiring amyloid PET images increases their value as disease and drug response biomarkers. The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

[18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

Jerney de Jongh, Nicki J. F. Verweij, Maqsood Yaqub, Christiaan J. van Denderen, Irene E. van der Horst-bruinsma, Joost C. J. Bot, Bouke J. H. Boden, Robert Hemke, Frank F. Smithuis, Willem F. Lems, Adriaan A. Lammertsma, Alexandre E. Voskuyl, Maarten Boers, Gerben J. C. Zwezerijnen, Conny J. van der Laken

Summary: Lesions detected on [F-18]fluoride PET scans often fall outside the scope of MRI and CR, with partial overlap with abnormalities seen on MRI (especially BME) and CR (especially ankylosis). PET activity shows the strongest association with BME on MRI and ankylosis on CR.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne

Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu

Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology

Mostafa Roya, Samaneh Mostafapour, Philipp Mohr, Laura Providencia, Zekai Li, Johannes H. van Snick, Adrienne H. Brouwers, Walter Noordzij, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Andor W. J. M. Glaudemans, Charalampos Tsoumpas, Riemer H. J. A. Slart, Joyce van Sluis

Summary: Recently, a new type of PET scanner with long axial field-of-view (LAFOV) has been introduced in clinical practice. Compared to conventional PET scanners, LAFOV scanners have a larger coverage and higher sensitivity, providing new opportunities for clinical applications, such as reducing scan time, decreasing the amount of radiotracer used, and using dynamic or parametric imaging. Emerging technologies like artificial intelligence and imaging with multiple radiotracers can further enhance the clinical application of LAFOV PET.

CANCERS (2023)

Article Respiratory System

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G. P. Gijtenbeek, Vincent van der Noort, Joachim G. J. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D. J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E. E. M. van den Borne, Harry J. M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

Summary: This study found that in patients with EGFR-mutated NSCLC, intercalated erlotinib with cisplatin-pemetrexed chemotherapy significantly prolonged progression-free survival compared to erlotinib monotherapy, but at the cost of increased toxicity.

ERJ OPEN RESEARCH (2022)

Review Pharmacology & Pharmacy

Role of Brain Imaging in Drug Development for Psychiatry

Johan A. den Boer, Erik J. F. de Vries, Ronald J. H. Borra, Aren van Waarde, Adriaan A. Lam-mertsma, Rudi A. Dierckx

Summary: This review discusses translational, diagnostic, and methodological issues in drug development for CNS disorders, with a focus on psychiatry. The role of preclinical models and brain imaging using PET and fMRI in early stages of drug development is critically reviewed. The review emphasizes the importance of collaborations between industry, academia, and phase I units in drug development. Brain imaging has revolutionized the study of psychiatric illnesses, providing insights at different levels of analysis and supporting preclinical and clinical drug development.

CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY (2022)

No Data Available